BLOOD SUGAR LEVELS IN THE NEW GROUP MECHANISM OF ACTION OF REDUCING DRUGS

Article Sidebar

Published: Oct 16, 2023
Keywords:
Keywords: diabetes Type 2, SGLT2, glyphozins, nglt-2 inhibitors, dapaglifozine, empaglifozine, canaglifozine

Main Article Content

Alijonov D.A.
Student 6 course of the Faculty of General Medicine
Bektasheva G.M.
Student 5 course of the Faculty of General Medicine
Kholmatova G.A.
PhD Head of the Department of Endocrinology and Hospital Therapy Andijan State Medical Institute Andijan Uzbekistan

Abstract

A review of this literature will focus on a new generation of hypoglycemic drugs, (glyphosins), a new group of hypoglycemic drugs with a mechanism of action associated with their reduction of glucose reabsorption in the kidneys and drug – dependent glucosuria-glyphosins.


 

Article Details

Issue
Vol. 2 No. 10 (2023): INTERNATIONAL JOURNAL OF ADVANCED RESEARCH IN EDUCATION, TECHNOLOGY AND MANAGEMENT
Section
Articles

References

DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58 (4): 773-95.

Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetes Med 2010; 27 (2): 136-42.

Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91 (2): 733-94.

Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. C Am Socnephral 2003; 14 (11): 2873-82.

Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+ / glucose cotransporter. Nature 1991; 350 (6316): 354-6.

Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54 (12): 3427-34.

Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev2011; 32 (4): 515-31.

Ehrenkranz Jr., Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21 (1): 31-8.

Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, Vaccaro N, Devineni D. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism 2014; 63 (10): 1296-303.

Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 8: 1335-80.

Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012; 61 (9):2199-204.

Wilding JP, Blonde L, Leiter LA, Cerdas S, Tong C, Yee J, Meininger G. Efficiency and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications 2015; 29 (3): 438-44.

Ferrannini E, Ramos SJ, Salsali a, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33 (10): 2217-24.

Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15:721-8. endocrin2_Layout 1 29.05.16 9: 44 Page 70

Stenlöf K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficiency and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-Week CANTATA-M study. Curr Med Res Apin 2014; 30 (2): 163-75.